Shares of Corbus Pharmaceuticals Holdings Inc. CRBP tumbled 10.23% to $8.51 Friday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP ...

Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.

Happy V-Day! Gorge on heart-shaped chocolate and ponder the implications of RFK Jr. being sworn in as health secretary. Today, we talk about that, as well as new cancer data from Corbus Pharma, Europe ...

Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...

Corbus Pharmaceuticals (CRBP) stock drops 12% after mixed Phase 1 trial results for its lead cancer candidate. Read more here.

Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP tumbled 10.22% to $8.78 Tuesday, on what proved to be an all-around mixed ...

NORWOOD, Mass. - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a $119 million market cap biopharmaceutical company, announced the release of an abstract detailing its Phase 1 clinical study of ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the abstract for its ...

Detailed price information for Corbus Pharmaceuticals Hldgs Inc (CRBP-Q) from The Globe and Mail including charting and trades.